Bienvenu(e) sur le site de l'Institut Necker Enfants Malades

Compréhension de l'arrêt de maturation oncogénique afin d'identifier des thérapies différentiantes spécifiques

de la science fondamentale :
  • dérégulation de la lymphopoïèse T humaine
à la recherche translationnelle :
  • leucémie
  • lymphome
Elizabeth Macintyre
Vahid Asnafi
Différentiation lymphoïde normale et pathologique

Elizabeth Macintyre, M.D-PhD FRCP/Path is Professor of Hematology at the Paris Descartes Medical School. She trained in internal Medicine and clinical and laboratory Hematology in the UK (Newcastle and UCL), did her PhD in Paris (St. Louis) and her post-doctoral fellowship in Harvard. She joined the Medical Faculty at Descartes in 1992 and has headed the Hematology Laboratory and the integrated Hematopathology Cancer programmes since 1999 and 2007, respectively.

Vahid Asnafi, M.D-PhD studied Medicine at Paris Descartes before specializing in laboratory Hematology. He obtained his PhD at Descartes in 2003 before doing his post-doctoral studies with Pierre Ferrier at CIML, Marseille. Returning to Necker in 2005, he was appointed full Professor of Hematology in 2012 and now heads the Onco-Hématology laboratory and well as co-directing the "Normal and Pathological Lymphoid Differentiation Team" at INEM


We study molecular mechanisms controlling TCR VDJ rearrangements during human T-cell ontogeny and their implication in (epi)genetic deregulation in T-lymphoid oncogenesis, in order to develop targeted therapeutics for leukemia and lymphoma.


Our research essentially involves analysis of the mechanisms controlling human T lymphoid ontogeny and oncogenic transformation in immature T lymphoid malignancies, particularly T-cell lymphoblastic acute leukemias (T-ALL) and lymphomas (T-LBL).

T-ALLs are malignant clonal proliferations arrested at specific stages of thymic differentiation. Oncogenic deregulation and physiological T lymphopoiesis, including the mechanisms regulating the somatic rearrangements leading to assembly of a T Cell Receptor (TCR), are intimately linked, which implies the contribution of physiological proliferative/apoptotic signals to the oncogenic process.

We have developed cellular and molecular characterisation of lymphoid malignancies in close collaboration with clinical cooperative and fundamental cognitive research groups in order to ensure optimal human tissue resource management and valorisation. All research projects are based on the principal that unravelling oncogenic pathways with an aim to improving treatment requires in-depth understanding of normal development of the system which has undergone deregulated tissue homeostasis.

These studies are possible due to close collaboration with the adult (Group for Research in Adult ALL or GRAALL and Lymphoma Study Association or LYSA) and pediatric (Société Française des Cancers de l’Enfant or SFCE Leukemia and Lymphoma committees) clinical cooperative groups, and with a variety of European networks, such as the EuroFLOW, EuroMRD, EuroClonality and Blueprint consortia.

Research objectives

Cellular and molecular characterization of lymphoid malignancies, with particular emphasis on T lymphoid oncogenesis:

  1. Read the language of antigen receptor (Immunoglobulin and T Cell Receptor) rearrangements in order to:
    • understand maturation arrest and lineage affiliation in order to improve classification of lymphoid malignancies
    • explore the potential oncogenic role of deregulated receptor rearrangements in the development of lymphoid malignancies
    • analyse TCR signalling function in T lymphoid oncogenesis
    • identify the potential for therapeutic correction of blocked lymphoid maturation secondary to deregulated receptor rearrangement
    • explore the mechanisms of action of Homeotic proteins during normal and pathological thymopoiesis
    • Explore the epigenetic regulation of human VDJ rearrangements during T lymphoid development (Blueprint)
  2. Explore Immature T/My/NK/ILC disorders in order to explore the interface between the lymphoid and myeloid lineages
  3. Study the Role of cytokine receptors, NOTCH1/FBXW7 pathway deregulation and aberrant signalling pathways in T-lymphoid oncogenesis
  4. Use innovative cellular and molecular techniques in order to improve integrated management of patients with leukaemia and lymphoma at diagnosis and follow-up, with particular emphasis on:
    • Ig/TCR markers for minimal residual disease personalized management in ALL and NHL
    • Multiparameter flow cytometry
    • Digital droplet quantification
    • High-throughput somatic onco- and immuno-genetics at diagnosis and follow-up

5 main publications

  • Trinquand A et al. (2016) Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia. Cancer Discov. Sep;6(9):972-85
  • Malcolm et al. (2016) NPM-ALK mimics thymic pre-TCR expansion requiring transient TCR expression for thymic egress and peripheral ALCL Nature Communications. 7:10087
  • Cieslak A et al. (2014) RUNX1 dependent RAG1 deposition instigates Human TCRα locus rearrangement. J Exp Med. Aug 25;211(9):1821-32
  • Trinquand A. et al. (2013) Towards a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-ALL: a GRAALL Study. Journal of clinical oncology Dec 1;31(34):4333-42
  • Dadi S et al. TLX homeodomain oncogenes mediate T-cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression. Cancer Cell. Apr 17;21(4):563-76
30 dernières publications


  • TAL1 activation in T-Cell acute lymphoblastic leukemia: A novel oncogenic 3' neoenhancer.  Smith C, Goyal A, Weichenhan D, Allemand E, Mayakonda A, Toprak U, Riedel A, Balducci E, Manojkumar M, Pejkovska A, Mücke O, Sollier E, Bakr A, Breuer K, Lutsik P, Hermine O, Spicuglia S, Asnafi V, Plass C, Touzart A. Haematologica. 2023 Jan 12. doi: 10.3324/haematol.2022.281583. Online ahead of print. PMID: 36632736
  • Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL. Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V. Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x. PMID: 36650499
  • Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL. Simonin M, Andrieu GP, Birsen R, Balsat M, Hypolite G, Courtois L, Graux C,bGrardel N, Cayuela JM, Huguet F, Chalandon Y, Le Bris Y, Macintyre EA, Gandemer V, Petit A, Rousselot P, Baruchel A, Bouscary D, Hermine O, Boissel N, Asnafi V.  Blood. 2023 Jan 4:blood.2022017755. doi: 10.1182/blood.2022017755. Epub ahead of print. PMID: 36599110.
  • 2022

  • How a Medical Association Can Make a Difference in a Crisis Situation. van Havre N, Orsini E, Almeida A, Gribben J, Bolanos N, Doeswijk R, Gaidano G, Mouhssine S, Döhner K, Grønbæk K, Porkka K, Macintyre E. Hemasphere. 2022 Aug 9;6(9):e765. doi: 10.1097/HS9.0000000000000765. PMID: 35966765
  • Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force. Dombrink I, Lubbers BR, Simulescu L, Doeswijk R, Tkachenko O, Dequeker E, Fraser AG, van Dongen JJM, Cobbaert C, Brüggemann M, Macintyre E. Hemasphere. 2022 May 20;6(6):e724. doi: 10.1097/HS9.0000000000000724. PMID: 35620593
  • One-Step Next-Generation Sequencing of Immunoglobulin and T-Cell Receptor Gene Recombinations for MRD Marker Identification in Acute Lymphoblastic Leukemia. Villarese P, Abdo C, Bertrand M, Thonier F, Giraud M, Salson M, Macintyre E. Methods Mol Biol. 2022;2453:43-59. doi: 10.1007/978-1-0716-2115-8_3. PMID: 35622319
  • Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. Bontoux C, Simonin M, Garnier N, Lhermitte L, Touzart A, Andrieu G, Bruneau J, Lengliné E, Plesa A, Boissel N, Baruchel A, Bertrand Y, Molina TJ, Macintyre E, Asnafi V. Mod Pathol. 2022 Sep;35(9):1227-1235. doi: 10.1038/s41379-022-01085-9. Epub 2022 May 13. PMID: 35562412.
  • Dynamics of broad H3K4me3 domains uncover an epigenetic switch between cell identity and cancer-related genes. Belhocine M, Simonin M, Abad Flores JD, Cieslak A, Manosalva I, Pradel L, Smith C, Mathieu EL, Charbonnier G, Martens JHA, Stunnenberg HG, Maqbool MA, Mikulasova A, Russell LJ, Rico D, Puthier D, Ferrier P, Asnafi V, Spicuglia S. Genome Res. 2022 Jul;32(7):1328-1342. doi: 10.1101/gr.266924.120. Epub 2021 Jun 23. PMID: 34162697
  • Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. Steimlé T, Dourthe ME, Alcantara M, Touzart A, Simonin M, Mondesir J, Lhermitte L, Bond J, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Balsat M, Vey N, Macintyre E, Ifrah N, Dombret H, Petit A, Baruchel A, Ruminy P, Boissel N, Asnafi V. Blood Cancer J. 2022 Jan 26;12(1):14. doi: 10.1038/s41408-022-00613-9. PMID: 35082269 
  • Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. Taj MM, Moorman AV, Hamadeh L, Petit A, Asnafi V, Alby-Laurent F, Vora A, Mansour MR, Gale R, Chevret S, Moppett J, Baruchel A, Macintyre E. Leukemia. 2022 Jan;36(1):263-266. doi: 10.1038/s41375-021-01334-x. Epub 2021 Jun 28. PMID: 34183766.


  • The EHA2021 Annual Congress Award Winners: Celebrating Excellence in Hematology.Gribben J, Macintyre E, Sonneveld P. Hemasphere. 2021 Jun 1;5(6):e585. doi: 10.1097/HS9.0000000000000585. PMID: 34095768
  • Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Touzart A, Mayakonda A, Smith C, Hey J, Toth R, Cieslak A, Andrieu GP, Tran Quang C, Latiri M, Ghysdael J, Spicuglia S, Dombret H, Ifrah N, Macintyre E, Lutsik P, Boissel N, Plass C, Asnafi V. Sci Transl Med. 2021 May 26;13(595):eabc4834. doi: 10.1126/scitranslmed.abc4834. PMID: 34039737.
  • Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. Simonin M, Schmidt A, Bontoux C, Dourthe MÉ, Lengliné E, Andrieu GP, Lhermitte L, Graux C, Grardel N, Cayuela JM, Huguet F, Arnoux I, Ducassou S, Macintyre E, Gandemer V, Dombret H, Petit A, Ifrah N, Baruchel A, Boissel N, Asnafi V. J Hematol Oncol. 2021 May 3;14(1):74. doi: 10.1186/s13045-021-01068-4. PMID: 33941203
  • Adenylate kinase 2 expression and addiction in T-ALL. Maslah N, Latiri M, Asnafi V, Féroul M, Bedjaoui N, Steimlé T, Six E, Verhoyen E, Macintyre E, Lagresle-Peyrou C, Lhermitte L, Andrieu GP. Blood Adv. 2021 Feb 9;5(3):700-710. doi: 10.1182/bloodadvances.2020002700. PMID: 33560378
  • PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. Andrieu GP, Kohn M, Simonin M, Smith CL, Cieslak A, Dourthe MÉ, Charbonnier G, Graux C, Huguet F, Lhéritier V, Dombret H, Spicuglia S, Rousselot P, Boissel N, Asnafi V. Blood. 2021 Nov 11;138(19):1855-1869. doi: 10.1182/blood.2020010081. PMID: 34125178
  • Toward Pediatric T Lymphoblastic Lymphoma Stratification Based on Minimal Disseminated Disease and NOTCH1/FBXW7 Status. Trinquand A, Plesa A, Abdo C, Subtil F, Aladjidi N, Rigaud C, Touzart A, Lhermitte L, Petit A, Michaux K, Jung C, Chassagne-Clement C, Asnafi V, Bertrand Y, Garnier N, Macintyre E. Hemasphere. 2021 Sep 6;5(10):e641. doi: 10.1097/HS9.0000000000000641. PMID: 34514345
  • Integrated omics approaches to predict T-LBL relapse risk. Andrieu GP, Asnafi V. Blood. 2021 Apr 29;137(17):2280-2282. doi: 10.1182/blood.2020009599. PMID: 33914078.
  • IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL. Blood. Simonin M, Lhermitte L, Dourthe ME, Lengliné E, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Ifrah N, Dombret H, Baruchel A, Macintyre E, Petit A, Boissel N, Asnafi V. 2021 Mar 25;137(12):1690-1694. doi: 10.1182/blood.2020007959. PMID: 33150353.
  • A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. Bond J, Krzywon A, Lhermitte L, Roumier C, Roggy A, Belhocine M, Kheirallah AA, Villarese P, Hypolite G, Garnache-Ottou F, Castaigne S, Boissel N, Asnafi V, Preudhomme C, Dombret H, Laurenti E, Macintyre E. Leukemia. 2021 Mar;35(3):724-736. doi: 10.1038/s41375-020-0965-z. Epub 2020 Jul 13. PMID: 32655144
  • Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. Marçais A, Lhermitte L, Artesi M, Laurent C, Durkin K, Hahaut V, Rosewick N, Suarez F, Sibon D, Cheminant M, Avettand-Fenoel V, Bruneau J, Georges M, Pique C, Van den Broeke A, Asnafi V, Hermine O. Leukemia. 2021 Mar;35(3):764-776. doi: 10.1038/s41375-020-0900-3. Epub 2020 Jun 17. PMID: 32555298.
  • 2020

  • Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation.
    Cieslak A, Charbonnier G, Tesio M, Mathieu E, Belhocine M, Touzart A, Smith C, Hypolite G, Andrieu GP, Martens JHA, Janssen-Megens E, Gut M, Gut I, Boissel N, Petit A, Puthier D, Macintyre E, Stunnenberg HG, Spicuglia S, Asnafi V.
    J Exp Med. 2020 Sep 7;217(9):e20192360.
  • Preclinical Efficacy of Humanized, non-FcγR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia
    Christine Tran Quang , Benedetta Zaniboni , Romain Humeau , Etienne Lengline , Marie-Emilie Dourthe , Rajkumar Ganesan , Sanjaya Singh, Justin M Scheer , Vahid Asnafi, Jacques Ghysdael
    Blood 2020 Jun 1; blood.2019003801. doi: 10.1182/blood.2019003801. Online ahead of print.
  • A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.
    Bond J, Krzywon A, Lhermitte L, Roumier C, Roggy A, Belhocine M, Kheirallah AA, Villarese P, Hypolite G, Garnache-Ottou F, Castaigne S, Boissel N, Asnafi V, Preudhomme C, Dombret H, Laurenti E, Macintyre E.
    Leukemia. 2020 Jul 13. doi: 10.1038/s41375-020-0965-z. Online ahead of print. PMID: 32655144
  • Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
    Kim R, Boissel N, Touzart A, Leguay T, Thonier F, Thomas X, Raffoux E, Huguet F, Villarese P, Fourrage C, Passini L, Hunault M, Lepretre S, Chevallier P, Braun T, Lhéritier V, Chantepie S, Maury S, Escoffre M, Tavernier E, Chalandon Y, Graux C, Macintyre E, Ifrah N, Asnafi V, Dombret H, Lhermitte L; on behalf the GRAALL group.
    Leukemia. 2020 Jan 28. doi: 10.1038/s41375-019-0685-4. [Epub ahead of print] PubMed PMID: 31992840.
  • CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia.
    Cordonnier G, Mandoli A, Cagnard N, Hypolite G, Lhermitte L, Verhoeyen E, Asnafi V, Dillon N, Macintyre E, Martens JHA, Bond J.
    Cell Rep. 2020 Jan 14;30(2):299-307.e3. doi: 10.1016/j.celrep.2019.12.026. PubMed PMID: 31940477.
  • Caution encouraged in NGS immunogenetic analyses in Acute Lymphoblastic Leukemia.
    Abdo C, Thonier F, Simonin M, Kaltenbach S, Valduga J, Petit A, Brüggemann M, Macintyre EA.
    Blood. 2020 May 21:blood.2020005613. doi:10.1182/blood.2020005613. Epub ahead of print. PMID: 32438392.
  • Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.
    Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Starza ID, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, Ferrero S, Macintyre E.
    Hemasphere. 2020 Apr 3;4(2):e347. doi: 10.1097/HS9.0000000000000347. PMID: 32309784; PMCID: PMC7162081.
  • Reducing Bureaucracy in Clinical Research: A Call for Action.
    Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S, Dreyling M.
    Hemasphere. 2020 Feb 26;4(2):e352. doi: 10.1097/HS9.0000000000000352. PMID: 32309789
  • 2019

  • Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia.
    Touzart A, Boissel N, Belhocine M, Smith C, Graux C, Latiri M, Lhermitte L, Mathieu EL, Huguet F, Lamant L, Ferrier P, Ifrah N, Macintyre E, Dombret H, Asnafi V, Spicuglia S.
    Haematologica. 2019 Sep 19. pii: haematol.2019.223677. doi: 10.3324/haematol.2019.223677. [Epub ahead of print] PubMed PMID: 31537687.
  • Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.
    Solly F, Angelot-Delettre F, Ticchioni M, Geneviève F, Rambaud H, Baseggio L, Plesa A, Debliquis A, Garnache-Ottou F, Roggy A, Campos L, Aanei C, Rosenthal-Allieri A, Georget MT, Lachot S, Jacob MC, Robillard N, Wuilleme S, Andre-Kerneis E, Cornet E, Salaun V, Bennami H, Lhoumeau AC, Arnoulet C, Jacqmin H, Neyman N, Latger-Cannard V, Massin F, Lainey E, Le Garff-Tavernier M, Costopoulos M, Roussel M, Mayeur-Rousse C, Eischen A, Raggeneau V, Derrieux C,Maurer M, Asnafi V, Trinquand A, Brouzes C, Lhermitte L.
    Cytometry A. 2019 Sep;95(9):1008-1018. doi: 10.1002/cyto.a.23844. Epub 2019 Jul 31. PubMed PMID: 31364809.
  • Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
    Alcantara M, Simonin M, Lhermitte L, Touzart A, Dourthe ME, Latiri M, Grardel N, Cayuela JM, Chalandon Y, Graux C, Dombret H, Ifrah N, Petit A, Macintyre E, Baruchel A, Boissel N, Asnafi V.
    Blood Adv. 2019 Jul 9;3(13):1981-1988. doi: 10.1182/bloodadvances.2018028993. PubMed PMID: 31270080; PubMed Central PMCID: PMC6616254.
  • Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.
    Touzart A, Lengliné E, Latiri M, Belhocine M, Smith C, Thomas X, Spicuglia S, Puthier D, Pflumio F, Leguay T, Graux C, Chalandon Y, Huguet F, Leprêtre S, Ifrah N, Dombret H, Macintyre E, Hunault M, Boissel N, Asnafi V.
    Clin Cancer Res. 2019 Apr 15;25(8):2483-2493. doi: 10.1158/1078-0432.CCR-18-1844. Epub 2019 Jan 18. PubMed PMID: 30659025.
  • DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia.
    Bond J, Touzart A, Leprêtre S, Graux C, Bargetzi M, Lhermitte L, Hypolite G, Leguay T, Hicheri Y, Guillerm G, Bilger K, Lhéritier V, Hunault M, Huguet F, Chalandon Y, Ifrah N, Macintyre E, Dombret H, Asnafi V, Boissel N.
    Haematologica. 2019 Aug;104(8):1617-1625. doi: 10.3324/haematol.2018.197848. Epub 2019 Jan 17. PubMed PMID: 30655366; PubMed Central PMCID: PMC6669163.
  • A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues.
    Derrieux C, Trinquand A, Bruneau J, Verkarre V, Lhermitte L, Alcantara M, Villarese P, Meresse B, Sibon D, Hermine O, Brousse N, Molina T, Cellier C, Cerf-Bensussan N, Malamut G, Macintyre E.
    J Mol Diagn. 2019 Jan;21(1):111-122. doi: 10.1016/j.jmoldx.2018.08.006. Epub 2018 Sep 28. PMID: 30268943.
  • 2018

  • The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies.
    Sujobert P, Le Bris Y, de Leval L, Gros A, Merlio JP, Pastoret C, Huet S, Sarkozy C, Davi F, Callanan M, Thieblemont C, Sibon D, Asnafi V, Preudhomme C, Gaulard P, Jardin F, Salles G, Macintyre E.
    Hemasphere. 2018 Dec 27;3(1):e169. doi: 10.1097/HS9.0000000000000169. eCollection 2019 Feb. PubMed PMID: 31723808; PubMed Central PMCID: PMC6745936.
  • Novel Intergenically Spliced Chimera, NFATC3-PLA2G15, Is Associated with Aggressive T-ALL Biology and Outcome
    Bond J, Tran Quang C, Hypolite G, Belhocine M, Bergon A, Cordonnier G, Ghysdael J, Macintyre E, Boissel N, Spicuglia S, Asnafi V.
    Mol Cancer Res. 2018 Mar;16(3):470-475. doi: 10.1158/1541-7786.MCR-17-0442. Epub 2018 Jan 12. PubMed PMID: 29330284.
  • Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
    Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V; French Acute Lymphoblastic Leukemia Study Group (FRALLE).
    Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19. PubMed PMID: 29051182.

    Chercheur statutaire
    Guillaume Andrieu
    +33 (0)1 40 61 54 36
    Vahid Asnafi
    Chercheur hospitalo-Universitaire
    +33 (0)1 44 49 49 14
    Chantal Brouzes
    +33 (0)1 44 49 49 32
    Bruno Canque
    Emilie Dourthe
    Praticien hospitalier
    +33 (0)1 40 61 54 36
    Sophie Kaltenbach
    Praticien hospitalier
    +33 (0)1 44 49 49 69
    Ludovic Lhermitte
    Enseignant Chercheur
    +33 (0)1 44 49 49 33
    Elizabeth Macintyre
    Chercheur hospitalo-Universitaire
    +33 (0)1 44 49 49 47
    Ambroise Marcais
    Praticien hospitalier
    Aurore Touzart
    Chercheur hospitalo-Universitaire
    +33 (0)1 44 49 40 98
    Chercheur non statutaire
    Omer Beganovic
    Assistant hospitalier universitaire
    Marianne Courgeon
    Assistant spécialiste
    Lucien Courtois
    +33 (0)1 40 61 54 36
    ITA statutaire
    Agata Cieslak
    Ingénieur(e) en biologie
    +33 (0)1 40 61 54 36
    Mélodie Culot
    Technicien(ne) en biologie
    Patrick Villarese
    +33 (0)1 44 49 49 41
    ITA non statutaire
    Mickaël Bonnet
    Ingénieur(e) en techniques biologiques
    Guillaume Charbonnier
    Jérôme Doss
    Technicien(ne) en biologie
    Martina Failla
    Assistant(e) en techniques biologiques
    Nicolas Gaidot
    +33 (0)1 40 61 54 36
    Camille Gillet
    Ingénieur(e) en techniques biologiques
    +33 (0)1 40 61 54 35
    Mélissandre Trenchand
    Ingénieur(e) en biologie
    Charlotte Smith
    +33 (0)1 40 61 54 36
    Manon Delafoy
    +33 (0)1 40 61 54 36
    Emilie Deruelle
    +33 (0)1 40 61 54 36
    El Mehdi Latiri
    +33 (0)1 40 61 54 35
    Valentine Louis
    Antoine Pinton
    Thomas Steimle
    +33 (0)1 44 49 49 41
    Inès Kassou
    Agathe Spaeth

    Notice: Undefined variable: contact_addr in /homepages/40/d483507699/htdocs/location.php on line 21
    S.A.R. la Princesse Caroline de Hanovre qui, à travers la Fondation Princesse Grace, soutient déjà la recherche medicale et tout ce qui contribue à soulager les enfants malades en France et dans le monde, a accepté de s'engager à nos cotés pour que ce centre de medecine moleculaire, tourné entre autres vers les pathologies des enfants, prenne de vitesse les maladies et continue à relever les defis actuels.

    INEM - Organigramme